Hisham Mehanna

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5050179/publications.pdf

Version: 2024-02-01

123	7,185	94433	64796
papers	citations	37 h-index	79 g-index

131	131	131	9397
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet, The, 2019, 393, 51-60.	13.7	697
2	Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancerâ€"systematic review and metaâ€analysis of trends by time and region. Head and Neck, 2013, 35, 747-755.	2.0	658
3	HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. Journal of the National Cancer Institute, 2016, 108, djv403.	6.3	580
4	Refeeding syndrome: what it is, and how to prevent and treat it. BMJ: British Medical Journal, 2008, 336, 1495-1498.	2.3	510
5	PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. New England Journal of Medicine, 2016, 374, 1444-1454.	27.0	503
6	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
7	Treatment and followâ€up of oral dysplasia â€" A systematic review and metaâ€analysis. Head and Neck, 2009, 31, 1600-1609.	2.0	330
8	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1â€"Low/Negative Recurrent or Metastatic HNSCC. JAMA Oncology, 2019, 5, 195.	7.1	235
9	Differences in the Recurrence and Mortality Outcomes Rates of Incidental and Nonincidental Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-Analysis of 21 329 Person-Years of Follow-up. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2834-2843.	3.6	150
10	HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology. Cancer Research, 2016, 76, 6598-6606.	0.9	128
11	Biomarkers in dysplasia of the oral cavity: A systematic review. Oral Oncology, 2009, 45, 647-653.	1.5	126
12	Acoustofluidic Salivary Exosome Isolation. Journal of Molecular Diagnostics, 2020, 22, 50-59.	2.8	104
13	Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease. European Journal of Cancer, 2013, 49, 1609-1618.	2.8	103
14	Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. Lancet Oncology, The, 2020, 21, e350-e359.	10.7	96
15	Refeeding syndrome â€" awareness, prevention and management. Head & Neck Oncology, 2009, 1, 4.	2.3	95
16	Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24. Journal of Medical Genetics, 2012, 49, 158-163.	3.2	95
17	Oropharyngeal carcinoma related to human papillomavirus. BMJ: British Medical Journal, 2010, 340, c1439-c1439.	2.3	93
18	Postoperative hypocalcemiaâ€"The difference a definition makes. Head and Neck, 2010, 32, 279-283.	2.0	91

#	Article	IF	Citations
19	Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Oncology, 2015, 33, 4202-4209.	1.6	86
20	Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025. Oral Oncology, 2015, 51, 341-348.	1.5	83
21	Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer. Clinical Cancer Research, 2019, 25, 5315-5328.	7.0	81
22	International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQâ€HN43: Phase IV. Head and Neck, 2019, 41, 1725-1737.	2.0	69
23	The binary oral dysplasia grading system: validity testing and suggested improvement. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 115, 87-94.	0.4	63
24	Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: Systematic review and metaâ€analysis. Head and Neck, 2013, 35, 1048-1055.	2.0	59
25	Open conservation partial laryngectomy for laryngeal cancer: A systematic review of English language literature. Cancer Treatment Reviews, 2012, 38, 203-211.	7.7	58
26	De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. Journal of Clinical Oncology, 2020, 38, 2552-2557.	1.6	58
27	Does Quality of Life Predict Long-term Survival in Patients With Head and Neck Cancer?. JAMA Otolaryngology, 2006, 132, 27.	1.2	56
28	Efficacy, outcomes, and complication rates of different surgical and nonsurgical treatment modalities for recurrent/residual oropharyngeal carcinoma: A systematic review and metaâ€analysis. Head and Neck, 2016, 38, 1855-1861.	2.0	54
29	PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomographyâ€“computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment, 2017, 21, 1-122.	2.8	52
30	Barriers to recruitment for surgical trials in head and neck oncology: a survey of trial investigators. BMJ Open, 2013, 3, e002625.	1.9	49
31	Transoral tongue base mucosectomy for the identification of the primary site in the work-up of cancers of unknown origin: Systematic review and meta-analysis. Oral Oncology, 2019, 91, 97-106.	1.5	49
32	Oral Dysplasia: Biomarkers, Treatment, and Follow-up. Current Oncology Reports, 2011, 13, 145-152.	4.0	45
33	Oropharyngeal cancer â€“ is it time to change management according to human papilloma virus status?. Current Opinion in Otolaryngology and Head and Neck Surgery, 2012, 20, 120-124.	1.8	44
34	Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic. Oral Oncology, 2020, 107, 104734.	1.5	44
35	Oncologic outcomes of open conservation laryngectomy for radiorecurrent laryngeal carcinoma. Cancer, 2011, 117, 2668-2676.	4.1	43
36	IGF-1R expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer. Carcinogenesis, 2015, 36, 648-655.	2.8	41

#	Article	IF	Citations
37	Geographic variation in human papillomavirusâ€“related oropharyngeal cancer: Data from 4 multinational randomized trials. Head and Neck, 2016, 38, E1863-9.	2.0	41
38	Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral Oncology, 2019, 88, 145-152.	1.5	40
39	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. Oral Oncology, 2020, 108, 104736.	1.5	40
40	Fungal laryngitis in immunocompetent patients. Journal of Laryngology and Otology, 2004, 118, 379-381.	0.8	39
41	Oncologic outcomes of transoral laser microsurgery for radiorecurrent laryngeal carcinoma: A systematic review and metaâ€analysis of Englishâ€language literature. Head and Neck, 2014, 36, 280-285.	2.0	39
42	WEE1 Inhibitor: Clinical Development. Current Oncology Reports, 2021, 23, 107.	4.0	38
43	Collagen Induces a More Proliferative, Migratory and Chemoresistant Phenotype in Head and Neck Cancer via DDR1. Cancers, 2019, 11, 1766.	3.7	36
44	Prediction of pharyngocutaneous fistulas after laryngectomy. Otolaryngology - Head and Neck Surgery, 2007, 136, s46-s49.	1.9	34
45	Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma. Head and Neck, 2018, 40, 1598-1604.	2.0	34
46	Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams). British Journal of Cancer, 2018, 118, 1672-1681.	6.4	32
47	Human Papillomavirus (HPV) Vaccine Effectiveness and Potential Herd Immunity for Reducing Oncogenic Oropharyngeal HPV-16 Prevalence in the United Kingdom: A Cross-sectional Study. Clinical Infectious Diseases, 2019, 69, 1296-1302.	5.8	30
48	External beam radiotherapy in differentiated thyroid carcinoma: A systematic review. Head and Neck, 2016, 38, E2297-305.	2.0	29
49	A Second National Survey of Health-Related Quality of Life Questionnaires in Head and Neck Oncology. Annals of the Royal College of Surgeons of England, 2009, 91, 420-425.	0.6	28
50	Circulating Tumour Cell Biomarkers in Head and Neck Cancer: Current Progress and Future Prospects. Cancers, 2019, 11, 1115.	3.7	28
51	Unsupervised morphological segmentation of tissue compartments in histopathological images. PLoS ONE, 2017, 12, e0188717.	2.5	27
52	Biomarkers in laryngeal dysplasia: A systematic review. Head and Neck, 2011, 33, 1170-1176.	2.0	26
53	Modelling human papillomavirus biology in oropharyngeal keratinocytes. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20180289.	4.0	23
54	Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: theWISTERIAtrial protocol. BMJ Open, 2020, 10, e033009.	1.9	23

#	Article	IF	Citations
55	Association between loss of Y chromosome and poor prognosis in male head and neck squamous cell carcinoma. Head and Neck, 2019, 41, 993-1006.	2.0	22
56	Toxicity Reduction in the Treatment of HPV Positive Oropharyngeal Cancer: Emerging Combined Modality Approaches. Frontiers in Oncology, 2018, 8, 439.	2.8	20
57	The Clinical Utility of Cell-Free DNA Measurement in Differentiated Thyroid Cancer: A Systematic Review. Frontiers in Oncology, 2018, 8, 132.	2.8	20
58	A digital score of tumourâ€associated stroma infiltrating lymphocytes predicts survival in head and neck squamous cell carcinoma. Journal of Pathology, 2022, 256, 174-185.	4.5	20
59	Re-feeding syndrome in head and neck â€“ Prevention and management. Oral Oncology, 2011, 47, 792-796.	1.5	19
60	Definition of locally recurrent head and neck squamous cell carcinoma: a systematic review and proposal for the Odenseâ€“Birmingham definition. European Archives of Oto-Rhino-Laryngology, 2020, 277, 1593-1599.	1.6	19
61	Malignancy Risk Analysis in Patients with Inadequate Fine Needle Aspiration Cytology (FNAC) of the Thyroid. PLoS ONE, 2012, 7, e49078.	2.5	18
62	LIHNCS - Lugolâ€™s iodine in head and neck cancer surgery: a multicentre, randomised controlled trial assessing the effectiveness of Lugolâ€™s iodine to assist excision of moderate dysplasia, severe dysplasia and carcinoma in situ at mucosal resection margins of oral and oropharyngeal squamous cell carcinoma: study protocol for a randomised controlled trial. Trials, 2013, 14, 310.	1.6	17
63	Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial. Oral Oncology, 2021, 113, 105112.	1.5	16
64	Salivary gland swellings. BMJ, The, 2012, 345, e6794-e6794.	6.0	15
65	Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer GroupÂposition paper based on the EORTC 1420 â€˜Best ofâ€™ and 24954 â€˜larynx preservationâ€™ study. European Journal of Cancer, 2018, 103, 69-77.	7.8	15
66	Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma. Oncotarget, 2019, 10, 5229-5244.	1.8	15
67	PTTG and PBF Functionally Interact with p53 and Predict Overall Survival in Head and Neck Cancer. Cancer Research, 2018, 78, 5863-5876.	0.9	14
68	Investigation of p16<scp>^{INK}</scp>^{4a} as a prognostic biomarker in oral epithelial dysplasia. Journal of Oral Pathology and Medicine, 2014, 43, 245-249.	2.7	13
69	Update on De-intensification and Intensification Studies in HPV. Recent Results in Cancer Research, 2017, 206, 251-256.	1.8	13
70	Will measuring quality of life in head and neck cancer alter individuals' treatment?. Current Opinion in Otolaryngology and Head and Neck Surgery, 2007, 15, 57-62.	1.8	12
71	Quality-of-life considerations in treatment of unresectable, recurrent head and neck cancer. Expert Review of Anticancer Therapy, 2010, 10, 345-352.	2.4	12
72	Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. Advanced Drug Delivery Reviews, 2021, 176, 113854.	13.7	12

#	Article	IF	Citations
73	Validation of tissue microarrays in oral epithelial dysplasia using a novel virtual-array technique. Journal of Clinical Pathology, 2012, 65, 1084-1087.	2.0	11
74	Considerations for a head and neck smoking cessation support programme; A qualitative study of the challenges in quitting smoking after treatment for head and neck cancer. European Journal of Oncology Nursing, 2018, 35, 54-61.	2.1	11
75	Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial. European Journal of Cancer, 2020, 124, 178-185.	2.8	11
76	The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dyingâ€"the head and neck cancer model. Cancer Causes and Control, 2021, 32, 459-471.	1.8	11
77	Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). European Journal of Cancer, 2021, 150, 232-239.	2.8	11
78	Recurrence of Papillary Thyroid Cancer: A Systematic Appraisal of Risk Factors. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1392-1406.	3.6	11
79	Routine restaging after primary non-surgical treatment of laryngeal squamous cell carcinomaâ€"aÂreview. Strahlentherapie Und Onkologie, 2021, 197, 167-176.	2.0	10
80	The anti-tumour activity of DNA methylation inhibitor 5-aza-2â€²-deoxycytidine is enhanced by the common analgesic paracetamol through induction of oxidative stress. Cancer Letters, 2021, 501, 172-186.	7.2	10
81	Features and prognostic utility of biopsy in oral squamous cell carcinoma. Head and Neck, 2016, 38, E1857-62.	2.0	9
82	Management of Advanced Head and Neck Cancer. New England Journal of Medicine, 2016, 375, 491-493.	27.0	9
83	Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4551-4563.	3.6	8
84	Upper Aerodigestive Tract Squamous Cell Carcinomas Show Distinct Overall DNA Methylation Profiles and Different Molecular Mechanisms behind WNT Signaling Disruption. Cancers, 2021, 13, 3014.	3.7	8
85	Surveillance of HPV-Positive Head and Neck Squamous Cell Carcinoma with Circulating and Salivary DNA Biomarkers. Critical Reviews in Oncogenesis, 2018, 23, 235-245.	0.4	8
86	Salivary gland swellings. Clinical Otolaryngology, 2013, 38, 58-65.	1.2	7
87	Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG. Oral Oncology, 2017, 71, 180-183.	1.5	7
88	Epithelium and Stroma Identification in Histopathological Images Using Unsupervised and Semi-Supervised Superpixel-Based Segmentation. Journal of Imaging, 2017, 3, 61.	3.0	7
89	Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 8229.	4.1	7
90	Soft tissue deposit in neck dissection specimen carries a poor prognosis in oral cancer: A matched pair analysis. Head and Neck, 2020, 42, 1783-1790.	2.0	7

#	Article	IF	Citations
91	Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial. European Journal of Cancer, 2021, 153, 242-256.	2.8	7
92	Feasibility of recruitment to an oral dysplasia trial in the United Kingdom. Head & Neck Oncology, 2012, 4, 40.	2.3	6
93	Postâ€Treatment Head and Neck Cancer Care: National Audit and Analysis of Current Practice in the United Kingdom. Clinical Otolaryngology, 2021, 46, 284-294.	1.2	6
94	Immediate Sample Fixation Increases Circulating Tumour Cell (CTC) Capture and Preserves Phenotype in Head and Neck Squamous Cell Carcinoma: Towards a Standardised Approach to Microfluidic CTC Biomarker Discovery. Cancers, 2021, 13, 5519.	3.7	6
95	Revised radiobiological modelling of the contribution of synchronous chemotherapy to the rate of grades 3â€“4 mucositis in head and neck cancer. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 733-738.	1.8	5
96	Laryngeal dysplasia and narrow band imaging: Secondary analysis of published data supports the role in patient followâ€up. Clinical Otolaryngology, 2018, 43, 1439-1442.	1.2	5
97	Head and neck surgery recommendations during the COVID-19 pandemic â€“ Author's reply. Lancet Oncology, The, 2020, 21, e417.	10.7	5
98	Human Papillomavirus E6/E7 mRNA detection by in situ hybridization in oral cavity squamous cell carcinoma. Archives of Oral Biology, 2020, 116, 104746.	1.8	5
99	Adapting Head and Neck Cancer Management in the Time of COVID-19. International Journal of Radiation Oncology Biology Physics, 2020, 107, 628-630.	0.8	5
100	Human papilloma virus detection in oropharyngeal carcinomas with in situ hybridisation using hand crafted morphological features and deep central attention residual networks. Computerized Medical Imaging and Graphics, 2021, 88, 101853.	5.8	5
101	A costâ€utility analysis comparing CT surveillance, PETâ€CT surveillance, and planned postradiation neck dissection for advanced nodal HPVâ€positive oropharyngeal cancer. Cancer, 2021, 127, 3372-3380.	4.1	5
102	The impact of institutional clinical trial recruitment versus hospital volume on survival outcomes of patients with head and neck cancer: An analysis of the PET-NECK trial outcomes, UKCRN portfolio, and Hospital Episode Statistics (HES) in England. Oral Oncology, 2018, 85, 40-43.	1.5	4
103	Development and validation of an improved classification and risk stratification system for carotid body tumors: Multinational collaborative cohort study. Head and Neck, 2021, 43, 3448-3458.	2.0	4
104	FACIAL PALSY AS THE PRESENTING COMPLAINT OF PERINEURAL SPREAD FROM CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. ANZ Journal of Surgery, 2007, 77, 191-193.	0.7	3
105	Management of advanced nodal disease in patients treated with primary chemoradiotherapy. Current Opinion in Oncology, 2016, 28, 201-204.	2.4	3
106	Epithelial Segmentation From In Situ Hybridisation Histological Samples Using A Deep Central Attention Learning Approach. , 2019, , .		3
107	Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient. International Journal of Molecular Sciences, 2021, 22, 7583.	4.1	3
108	Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale. Quality of Life Research, 2022, 31, 841-853.	3.1	3

#	Article	IF	Citations
109	Oral human papillomavirus (HPV) and associated factors among healthy populations: The design of the PROGRESS (PRevalence of Oral hpv infection, a Global aSSessment) study. Contemporary Clinical Trials, 2022, 115, 106630.	1.8	3
110	The BROADEN study: The design of an observational study to assess the absolute burden of HPV-related head and neck cancers. Contemporary Clinical Trials, 2021, , 106631.	1.8	3
111	Exploring the views of patients' and their family about patientâ€initiated followâ€up in head and neck cancer: A mixed methods study. European Journal of Cancer Care, 2022, 31, .	1.5	3
112	Differential Expression of Potential Biomarkers of Oral Squamous Cell Carcinoma Development. Head and Neck Pathology, 2021, 15, 1127-1136.	2.6	2
113	Symptomâ€based remote assessment in postâ€treatment head and neck cancer surveillance: A prospective national study. Clinical Otolaryngology, 2022, 47, 561-567.	1.2	2
114	Surgical trials in head & neck cancer â€“ Are you serious?. Oral Oncology, 2013, 49, 843-844.	1.5	1
115	The role of PET CT in the management of advanced nodal head neck cancer post chemoradiotherapy. Translational Cancer Research, 2016, 5, S932-S932.	1.0	1
116	FBXL7 Body Hypomethylation Is Frequent in Tumors from the Digestive and Respiratory Tracts and Is Associated with Risk-Factor Exposure. International Journal of Molecular Sciences, 2022, 23, 7801.	4.1	1
117	Advanced head and neck cancer: is there a role for fluorodeoxyglucose PET/computed tomography?. Nuclear Medicine Communications, 2009, 30, 2-4.	1.1	0
118	Surgery for Primary Hyperparathyroidism. , 2014, , 253-258.		0
119	Smoking after cancer: A qualitative study of the challenges in quitting smoking after a diagnosis of, and treatment for, head and neck cancer. European Journal of Surgical Oncology, 2016, 42, S253.	1.0	0
120	In Regard to Beadle and Anderson. International Journal of Radiation Oncology Biology Physics, 2018, 102, 229-230.	0.8	0
121	Safety and Feasibility of Surgery for Oropharyngeal Cancers During the SARS-CoV-2-Pandemic. Frontiers in Oncology, 2021, 11, 651123.	2.8	0
122	Model-Based Correction of Segmentation Errors in Digitised Histological Images. Communications in Computer and Information Science, 2017, , 718-730.	0.5	0
123	Should We De-escalate Treatment for HPV Positive Oropharyngeal Head and Neck Cancer?. , 2018, , 165-170.		0